Evidence map›Paper›PMID 42158454›Full record

ArticleFrontiers in bioengineering and biotechnology2026

Quantitative determination of trace principal components with high specific activity in menotropins.

Yue Sun, Heyang Li, Xinyue Hu, Shuqing Luo, Xiaoming Zhang, Lyuyin Wang, Yi Li, Ping Lyu, Jing Li

Abstract read
In one paragraph

Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yue Sun *National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Heyang Li *National Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Xinyue HuNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Shuqing LuoChemical Drug Analysis Laboratory, Ningbo Institute for Drug Control, Ningbo, China.
Xiaoming ZhangNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Lyuyin WangNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Yi LiNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Ping LyuNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.
Jing LiNational Institutes for Food and Drug Control, State Key Laboratory of Drug Regulatory Science, NMPA Key Laboratory for Quality Research and Evaluation of Chemical Drugs, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Menotropins is a mixture of gonadotropin glycoproteins extracted from the urine of postmenopausal women. Its composition is complex, with active components including follicle-stimulating hormone (FSH), luteinizing hormone (LH), and human chorionic gonadotropin (hCG), in addition to many unknown components. The current standards for menotropins rely exclusively on in vivo animal models for the bioactivity control of FSH and LH. However, these methods are complex and highly variable. Moreover, they fail to accurately quantify the high specific bioactivities of FSH and LH, which in turn impairs the batch-to-batch consistency of the final product. To date, there is no appropriate method for accurately quantifying these trace principal components with high specific activities. Methods: A reversed-phase high-performance liquid chromatography (RP-HPLC) method was established in the present study to quantify the α-subunits content common to FSH, LH, and hCG, as well as the FSH content, while simultaneously enabling purity assessment in menotropins and their formulations. The α-subunit peaks of FSH, LH, and hCG and the β-subunit peak of FSH were selected as the target peaks, with recombinant human FSH (rhFSH) employed as the external standard for quantification. Purity was calculated as the percentage of the sum of the α- and β-subunit peak areas using the area normalization method in chromatographic analysis. The validation procedure strictly followed ICH Q2(R1) guidelines and the requirements of the Chinese Pharmacopoeia, with evaluations of specificity, precision, linearity,accuracy, robustness, stability, limit of detection (LOD), and limit of quantification (LOQ). In addition to developing this HPLC method, this study conducted large-scale real-world sample analysis and head-to-head comparisons with the animal assay. Results: Methodological validation demonstrated that the developed RP-HPLC assay possessed excellent linearity, with correlation coefficients (R Discussion: As a result of its operational simplicity, accuracy, and high sensitivity, this HPLC method enables the simultaneous quantification of the total α-subunits and FSH content in menotropins, as well as assessment of their purity. It successfully addresses the analytical challenges posed by the complex matrix, abundant non-target proteins, and extremely low content of active ingredients in conventional menotropins products. It thereby provides a robust analytical tool for enhancing product quality control and safety assurance.

Indexed as

biological potencymenotropinspurity assessmentquantificationα-subunitβ-subunit

Identifiers

PMID42158454
PMCPMC13180910

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.